New drug cocktail aims to boost lung cancer surgery success

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntarily sign informed consent and agree to comply with the protocol requirements; 2. Aged ≥18 years and ≤75 years, regardless of gender; 3. Expected survival time ≥3 months; 4. Patients with non-small cell lung cancer; 5. One of the EGFR sensitive mutation types detected in the tumor tissue; 6. Agree to provide archived primary tumor tissue specimens obtained within 12 months or fresh tissue samples; 7. Undergo pulmonary function testing within 28 days prior to the first dose; 8. ECOG performance status score of 0 or 1; 9. No severe cardiac dysfunction; 10. Organ function levels must meet the required criteria; 11. Urine protein ≤1+ or \<1000 mg/24h; 12. For premenopausal women of childbearing potential, a serum pregnancy test must be performed within 7 days before starting treatment, and the serum pregnancy test must exclude pregnancy; patients must not be lactating; all enrolled trial participants must use adequate barrier contraceptive measures throughout the entire treatment period and for 7 months after the end of treatment. Exclusion Criteria: 1. SCLC, mixed SCLC and NSCLC, or other non-NSCLC pathological types; 2. Trial participants who subsequently receive only segmentectomy or wedge resection; 3. Trial participants deemed surgically inoperable by the study center's surgical evaluation; 4. Undergoing major surgery within 4 weeks prior to the first dose, among others; 5. Previous receipt of systemic anti-tumor therapy for non-small cell lung cancer other than that for this study, among others; 6. Receiving long-term systemic corticosteroid therapy with prednisone \>10 mg/day within 2 weeks prior to randomization, among others; 7. History of severe heart disease or cerebrovascular disease; 8. Prolonged QTc interval, complete left bundle branch block, etc.; 9. Any thrombotic event within 6 months prior to screening; 10. Trial participants with known or suspected interstitial lung disease, among others; 11. Diagnosis of active malignant tumors within 5 years prior to study randomization; 12. Hypertension inadequately controlled by two antihypertensive medications; 13. Trial participants with poorly controlled blood glucose; 14. Severe infection occurring within 4 weeks prior to study randomization, among others; 15. Presence of large serous cavity effusion, or serous cavity effusion with symptoms, etc.; 16. Imaging findings indicating tumor invasion or encasement of the abdomen, chest, etc.; 17. Severe non-healing wounds, ulcers, or fractures within 4 weeks prior to signing informed consent; 18. Trial participants with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent; 19. Inflammatory bowel disease, history of extensive bowel resection, history of immune-related enteritis, etc.; 20. History of allergy to the investigational drug, etc.; 21. History of solid organ transplantation, autologous or allogeneic stem cell transplantation; 22. Positive for human immunodeficiency virus antibodies, active hepatitis B virus infection, or hepatitis C virus infection; 23. History of severe neurological or psychiatric disorders; 24. Trial participants planning to receive or having received live vaccines within 28 days prior to study randomization; 25. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial due to complications or other circumstances.